Clinical trials: Cancer of Thorax
Non-Small Cell Lung Cancer
Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo…
- Trial name
- NCT03117049
- Testing
- ONO-4538, Carboplatin, Paclitaxel
- Where
- 135 sites in Japan, South Korea and 1 more
- Volunteers
- 550 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.
- Trial name
- NCT00423449
- Testing
- vorinostat, Gemcitabine, Platinum-based agent
- Volunteers
- 61 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Adult, Breast Cancer
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer
- Trial name
- NCT03149549
- Testing
- CX-2009
- Where
- 26 sites in United States, Netherlands and 2 more
- Volunteers
- 99 people
- Sponsor
- CytomX Therapeutics
Squamous Non-Small Cell Lung Cancer
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
The main purpose of the study was to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with treatment-naïve advanced squamous non-small-cell lung…
- Trial name
- NCT03717155
- Testing
- Avelumab, Cetuximab, Gemcitabine
- Where
- 20 sites in Hungary, Serbia and 1 more
- Volunteers
- 43 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non-Small-Cell-Lung Cancer (NSCLC)
Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients
The purpose of this study is to help researchers investigate if a new imaging agent named 18F-FMISO can predict if patients with lung cancer will respond to standard therapy, as well as whether disease will reoccur in the future.
- Trial name
- NCT02016872
- Testing
- 18F-FMISO, PET/CT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Tumors
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients…
- Trial name
- FALCON (NCT00653939)
- Testing
- Fosbretabulin, Carboplatin, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mateon Therapeutics
Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT00602030
- Testing
- Entinostat, Erlotinib
- Where
- 30 sites in United States
- Volunteers
- 141 people
- Sponsor
- Syndax Pharmaceuticals
Lung Cancer
Phase II Study of ZD6474 in Advanced NSCLC
The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor.
- Trial name
- NCT00290537
- Testing
- ZD6474, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small-cell Lung Cancer
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
This study will assess the efficacy of AUY922, when administered weekly at 70 mg/m2, in adult patients with advanced Non-small-cell Lung Cancer (NSCLC), who have received at least two prior lines of chemotherapy.
- Trial name
- NCT01124864
- Testing
- AUY922
- Where
- 22 sites in United States, Canada and 8 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.
- Trial name
- NCT06039384
- Testing
- INCB099280, adagrasib
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 6 people
- Sponsor
- Incyte Corporation
Non-Small Cell Lung Cancer
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.
- Trial name
- NCT02584634
- Testing
- Avelumab, PF-06463922, Crizotinib
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 43 people
- Sponsor
- Pfizer
Small Cell Lung Cancer (SCLC)
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
The purpose of this research study is to see if Abraxane and Gemcitabine given together will be effective in treating small cell cancer that has progressed after one line of treatment.
- Trial name
- NCT02769832
- Testing
- Nab-paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Muhammad Furqan
Stage IV Non-small Cell Lung Cancer
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in patients with stage IV non-squamous…
- Trial name
- NCT03559049
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer, Male Breast Cancer
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with trastuzumab and to see how well they work in treating patients with metastatic breast canceror breast cancer that has…
- Conditions
- Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00258349
- Testing
- vorinostat, trastuzumab
- Where
- 25 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC
This is a randomized Phase II study which is designed to determine the impact of stereotactic radiotherapy and durvalumab on quality-of-life and oncologic outcomes in patients with advanced non-small cell lung cancer.
- Trial name
- NCT04786093
- Testing
- Stereotactic radiation therapy, Durvalumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic Non-small Cell Lung Cancer
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab (+) berahyaluronidase alfa vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult Japanese participants…
- Trial name
- NCT06212752
- Testing
- Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin
- Where
- 18 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small…
- Trial name
- NCT03563716
- Testing
- Atezolizumab, Tiragolumab
- Where
- 40 sites in United States, France and 4 more
- Volunteers
- 135 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer, Carcinoma
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
This was a Phase 1/2, open-label, multicenter, single-arm study of combination therapy with ensartinib, an anaplastic lymphoma kinase (ALK) inhibitor, and durvalumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, in…
- Conditions
- Non-small Cell Lung Cancer, Carcinoma, NSCLC
- Trial name
- NCT02898116
- Testing
- Ensartinib, Durvalumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ludwig Institute for Cancer Research
Non-Small Cell Lung Cancer
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III…
- Trial name
- NCT00621049
- Testing
- Docetaxel/Carboplatin/Bevacizumab/Erlotinib, Docetaxel/Carboplatin
- Where
- 26 sites in United States
- Volunteers
- 112 people
- Sponsor
- SCRI Development Innovations, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.